Featured posts for SRF News and where featured posts should appear.
In this update, we review two recent papers that address the question of people with type 2 diabetes who take metformin living longer than people without the disease who don’t, but without the flaw in the 2014 study. We find that, as expected, metformin is a good diabetes drug but shows no sign of being a longevity therapeutic.
SENS Research Foundation (SRF) is launching its campaign Sponsor a Student to increase charitable donations that will allow it to hire more student researchers and teach them that aging is not indisputable. Sponsoring a student dramatically transforms a young person’s life, giving them a chance to conduct world-class research and learn more about the career that awaits them.
TTR cardiac amyloid contributes to heart failure and appears to limit the lives of the longest-lived humans. One AmyloSENS antibody shows high promise to remove this amyloid and restore function in the aging heart in an early-stage clinical trial. A second such antibody is coming close behind it, and a tiny number of people’s immune systems appear to generate such antibodies on their own.
June 23, 2023 – SRF had the Grand Opening of our expanded Research Center in Mountain View, CA. In attendance were local and state dignitaries, members of the SRF Board, SRF senior staff and scientific leads, SRF staff and Education program participants, and a number of distinguished and welcome guests.
Another clinical trial has now proven that a second AmyloSENS rejuvenation biotechnology that clears beta-amyloid aggregates from the brain also slows down the slide into dementia in people in the early stages of Alzheimer’s disease, but this development is only the beginning.
Docuthon is the world’s first documentary-creating competition on AI-powered drug discovery, providing an opportunity for every talented filmmaker to get involved in a cutting-edge industry, share a terrific science story, and inspire the next generation of scientists in longevity.
When blood from a biologically aged animal is transfused into a young one, the young animal suffers “pro-aging” effects. By contrast, reducing the burden of “pro-aging” signaling factors in old blood is not enough to remove existing damage from a similar-aged mouse’s biologically aged tissues.
UNITY Biotechnology was the first senolytic startup out of the gate, and the failure of its Phase II trial in osteoarthritis was a crushing disappointment. A careful look back at the underlying science and three new scientific papers give us a good idea why and suggest ways to move forward.
A supporter asks us to compare the expected benefits of Cyclarity’s UDP-003 to chelation therapy. Although both target the age-related scourge of atherosclerotic cardiovascular disease (ASCVD), EDTA (if it works) dampens down the worst aspects of having ASCVD, while UPD-003 is a SENS “damage-repair” therapeutic which is expected to remove the underlying damage itself and reverse the disease process.
A significant and vital step forward for the longevity field: the Biomarkers of Aging Consortium. Formed of a diverse group of academic and industry members, the Consortium seeks to “establish reliable biomarkers of aging, particularly for the identification and evaluation of longevity interventions. Learn more…
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2023 SENS Research Foundation – ALL RIGHTS RESERVED
